Get Your Personalized Supplement StackSupplement Stack Quiz

Lactobacillus Rhamnosus Hn001

Also known as: L. rhamnosus HN001, probiotic strain HN001, Lactobacillus rhamnosus HN001

Overview

Lactobacillus rhamnosus HN001 is a specific, well-researched probiotic strain of *Lactobacillus rhamnosus*, a gram-positive lactic acid bacterium commonly found in the human gut and fermented foods. It is utilized as a dietary supplement primarily to support gut health, modulate immune function, and potentially influence mental well-being and prevent allergic conditions. This particular strain has been the subject of several randomized controlled trials and systematic reviews, especially concerning its application during the perinatal period for allergy prevention, and its potential impact on maternal mental health. While research on HN001 is moderately mature, with varying but generally high-quality evidence, its efficacy is most strongly supported for atopic disease prevention and postpartum mood regulation. It is generally available in capsule or powder forms and is known for its resilience in the gastrointestinal tract.

Benefits

Lactobacillus rhamnosus HN001 offers several evidence-based benefits, with varying strengths of evidence: * **Atopic Eczema Prevention:** Strong evidence from a systematic review and meta-analysis indicates that perinatal administration of *L. rhamnosus* (including HN001) significantly reduces the risk of atopic eczema in children. A relative risk reduction of approximately 42% (RR ~0.58; 95% CI 0.41–0.82; p=0.002) was observed at 2 years of age when used as a single strain. This benefit is particularly relevant for infants at high risk of developing allergies. * **Postpartum Mental Health:** Moderate to strong evidence from a randomized double-blind placebo-controlled trial suggests that *L. rhamnosus* HN001 supplementation during pregnancy can reduce symptoms of postpartum depression and anxiety, indicating potential anxiolytic effects. This benefit is specific to pregnant women and the postpartum period. * **Immune Function and Respiratory Illness:** While specific data on HN001 alone is limited, meta-analyses of probiotics, including *L. rhamnosus* strains, suggest a modest reduction in the duration of common respiratory infections (by about 0.5 to 1 day). The evidence for HN001 specifically is less direct for this benefit. * **Metabolic and Weight Management:** Current high-quality randomized controlled trials in adults with pre-diabetes or overweight women with PCOS have shown no significant clinical benefit of HN001 on metabolic markers such as HbA1c, gut bacteria abundance, or lipid profiles. Therefore, there is no strong evidence to support its use for weight loss or metabolic improvement.

How it works

Lactobacillus rhamnosus HN001 exerts its effects through several mechanisms. It modulates the immune system by enhancing regulatory T-cell responses and balancing Th1/Th2 cytokine profiles, which is believed to be crucial for its role in allergy prevention and mental health. The strain may also influence gut-brain axis signaling, contributing to its anxiolytic effects. Furthermore, HN001 produces lactic acid, which lowers gut pH, creating an unfavorable environment for pathogenic bacteria. It competes with harmful microorganisms for nutrients and adhesion sites, thereby supporting gut barrier integrity and maintaining a balanced gut microbiota. Its acid- and bile-tolerant properties ensure survival through the gastrointestinal tract, facilitating its colonization and beneficial actions.

Side effects

Lactobacillus rhamnosus HN001 is generally considered safe and well-tolerated, with no serious adverse events reported in clinical trials. The most commonly observed side effects are mild and rare, primarily involving transient gastrointestinal symptoms such as bloating, gas, or mild abdominal discomfort. These symptoms typically resolve on their own as the body adjusts to the supplement. There are no significant drug interactions or contraindications specifically documented for HN001 in healthy populations, including pregnant women, where it has been extensively studied and found safe. However, as with all probiotics, individuals who are severely immunocompromised (e.g., those with central venous catheters, recent surgery, or severe underlying diseases) should exercise caution and consult a healthcare professional before use, due to a theoretical risk of bacteremia, although no specific cases linked to HN001 have been reported. No specific safety concerns have been identified for HN001 in these vulnerable populations, but general probiotic precautions apply.

Dosage

The effective daily dosage of Lactobacillus rhamnosus HN001, as established in clinical trials, typically ranges from 6×10^9 to 12×10^9 colony-forming units (CFU). For the prevention of atopic eczema, studies involving perinatal administration commonly use a dose of 6×10^9 CFU per day, initiated during pregnancy and continued postnatally. Similar dosing has been employed in mental health studies during pregnancy. While there is no established maximum safe dose, doses up to 10^10 CFU per day are generally considered safe and well-tolerated. For optimal efficacy, particularly for allergy prevention, the timing of administration is crucial, often requiring continuous dosing throughout the perinatal period. For mental health benefits, continuous supplementation during pregnancy is recommended to observe postpartum effects. HN001 is available in various forms, including capsules and powders, and its acid- and bile-tolerant nature ensures good survival through the digestive tract.

FAQs

Is HN001 effective for weight loss?

Current randomized controlled trials indicate that *L. rhamnosus* HN001 does not provide significant benefits for weight loss or improvement in metabolic markers in adults with pre-diabetes or overweight individuals.

Can HN001 prevent allergies?

Yes, strong evidence supports that perinatal administration of *L. rhamnosus* HN001 can significantly reduce the risk of atopic eczema in children, particularly when given to mothers during pregnancy and continued postnatally.

Is it safe to take HN001 during pregnancy?

Yes, clinical trials have demonstrated that *L. rhamnosus* HN001 is safe for use during pregnancy and has shown benefits for both maternal mental health and infant allergy prevention.

How long does it take to see benefits from HN001?

For allergy prevention, effects are typically observed at 2 years of age following perinatal supplementation. For mental health benefits, improvements in postpartum depression and anxiety are noted after supplementation throughout pregnancy.

Research Sources

https://pmc.ncbi.nlm.nih.gov/articles/PMC9576646/ – This systematic review and meta-analysis of RCTs found that perinatal administration of *Lactobacillus rhamnosus* (including HN001) significantly reduced the risk of atopic eczema in children, with a relative risk reduction of approximately 42% at 2 years of age. The study highlights the efficacy of this probiotic strain in allergy prevention, though it noted moderate heterogeneity across studies.
https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0199041 – This randomized controlled trial and meta-analysis investigated the effects of *L. rhamnosus* HN001 supplementation during pregnancy. It reported that HN001 reduced postpartum symptoms of depression and anxiety in pregnant women, suggesting anxiolytic effects. The study provides evidence for the probiotic's role in maternal mental health.
https://www.ffhdj.com/index.php/FunctionalFoodScience/article/view/1115/4402 – This article discusses randomized controlled trials that investigated the effects of *L. rhamnosus* HN001 on metabolic health and weight management in adults with pre-diabetes and overweight women with PCOS. The findings indicated no significant clinical benefit of HN001 on HbA1c, gut bacteria abundance, or lipid profiles, suggesting it is not effective for these conditions.
https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/effectiveness-of-probiotics-on-the-duration-of-illness-in-healthy-children-and-adults-who-develop-common-acute-respiratory-infectious-conditions-a-systematic-review-and-metaanalysis/4382D42135F5C78FFA96E5F4C581944D – This systematic review and meta-analysis examined the effectiveness of probiotics, including *L. rhamnosus* strains, on the duration of common respiratory infections. It found a modest reduction in illness duration by about 0.5 to 1 day, suggesting a general immune-modulating effect of probiotics, though specific data on HN001 alone was limited.